[1] 王心怡, 龙囿霖, 方可, 等. 复合终点在临床研究中的应用与挑战[J]. 中国循证医学杂志, 2023, 23(12): 1465- 1471.
[2] 彭菊聪, 孙甜甜, 李伦, 等. 复合终点[J]. 中国循证儿科杂志, 2012, 7(4): 305-307.
[3] Chi G Y H. Some issues with composite endpoints in clinical trials[J]. Fundamental & Clinical Pharmacology, 2005, 19(6): 609-619.
[4] Montori V M, Permanyer-Miralda G, Ferreira-González I, et al. Validity of composite end points in clinical trials[J]. BMJ, 2005, 330(7491): 594-596.
[5] Tomlinson G, Detsky A S. Composite end points in randomized trials[J]. JAMA, 2010, 303(3): 267.
[6] Shaikh A, Ochani R K, Khan M S, et al. Contribution of individual components to composite end points in contemporary cardiovascular randomized controlled trials[J]. American Heart Journal, 2020, 230: 71-81.
[7] Evans S R, Follmann D. Using outcomes to analyze patients rather than patients to analyze outcomes: A step toward pragmatism in benefit: Risk evaluation[J]. Statistics in Biopharmaceutical Research, 2016, 8(4): 386-393.
[8] Montepiedra G, Yuen C M, Rich M L, et al. Totality of outcomes: A different paradigm in assessing interventions for treatment of tuberculosis[J]. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2016, 4: 9-13.
[9] Follmann D, Fay M P, Hamasaki T, et al. Analysis of ordered composite endpoints[J]. Statistics in Medicine, 2020, 39(5): 602-616.
[10] Evans S R, Rubin D, Follmann D, et al. Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR)[J]. Clinical Infectious Diseases, 2015, 61(5): 800-806.
[11] Chen J, Liang Q Q, Chen X Y, et al. Ceftazidime/avibactam versus polymyxin B in the challenge of carbapenemresistant Pseudomonas aeruginosa infection[J]. Infection and Drug Resistance, 2022, 15: 655-667.
[12] Chow R D, Wankhedkar K P, Mete M. Patients' preferences for selection of endpoints in cardiovascular clinical trials[J]. Journal of Community Hospital Internal Medicine Perspectives, 2014, 4(1): 22643.
[13] Thomas M, Fraenkel L, Boonen A, et al. Patient preferences to value health outcomes in rheumatology clinical trials: Report from the OMERACT special interest group[J]. Seminars in Arthritis and Rheumatism, 2021, 51(4): 919-924.
[14] 吴晓蕾, 史梦龙, 张晨瑶, 等. 以患者为中心药物研发相关概念介绍[J]. 中国循证医学杂志, 2023, 23(12): 1472-1477.
[15] Lu Y, Zhao Q, Zou J Y, et al. A composite endpoint for treatment benefit according to patient preference[J]. Statistics in Biopharmaceutical Research, 2022, 14(4): 408- 422.
[16] Van Eijk R P A, Van den Berg L H, Lu Y. Composite endpoint for ALS clinical trials based on patient preference: Patient-Ranked Order of Function (PROOF)[J]. Journal of Neurology, Neurosurgery & Psychiatry, 2022, 93(5): 539-546.
[17] Van Eijk R P A, De Jongh A D, Nikolakopoulos S, et al. An old friend who has overstayed their welcome: The ALSFRS-R total score as primary endpoint for ALS clinical trials[J]. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22(3/4): 300-307.
[18] Petersiel N, Davis J S, Meagher N, et al. Combination of antistaphylococcal β-lactam with standard therapy compared to standard therapy alone for the treatment of methicillin-resistant Staphylococcus aureus bacteremia: A post hoc analysis of the CAMERA2 trial using a desirability of outcome ranking approach[J]. Open Forum Infectious Diseases, 2024, 11(5): ofae181.
[19] Guidry C A, Chollet-Hinton L, Baker J, et al. Desirability of outcome ranking and response adjusted for antibiotic risk (DOOR/RADAR) post hoc analysis supports equipoise for antibiotic initiation strategies in intensive care unit-acquired pneumonia[J]. Surgical Infections, 2024, 25(3): 221-224.
[20] Howard-Anderson J, Hamasaki T, Dai W X, et al. Improving traditional registrational trial end points: Development and application of a desirability of outcome ranking end point for complicated urinary tract infection clinical trials[J]. Clinical Infectious Diseases, 2023, 76(3): e1157-e1165.
[21] Jacobs M A, Schmidt S, Hall D E, et al. A surgical desirability of outcome ranking (DOOR) reveals complex relationships between race/ethnicity, insurance type and neighborhood deprivation[J]. Annals of Surgery, 2023, 279(2): 246-257.
[22] Neaton J D, Gray G, Zuckerman B D, et al. Key issues in end point selection for heart failure trials: Composite end points[J]. Journal of Cardiac Failure, 2005, 11(8): 567-575.
[23] Cordoba G, Schwartz L, Woloshin S, et al. Definition, reporting, and interpretation of composite outcomes in clinical trials: Systematic review[J]. BMJ, 2010, 341(183): c3920.
[24] 刘志国, 李海霞, 王蕾, 等. 皮内针调理肝肺法治疗慢性难治性咳嗽的临床效果[J]. 中国医药导报, 2020, 17(30): 173-177.
[25] Yang J W, Wang L Q, Zou X, et al. Effect of acupuncture for postprandial distress syndrome[J]. Annals of Internal Medicine, 2020, 172(12): 777-785.
[26] 胡斌, 马巧琳, 杨帆, 等. 基于真实世界研究方法的医学研究进展[J]. 中医临床研究, 2022, 14(22): 141-145.
[27] 刘保延. 真实世界的中医临床科研范式[J]. 中医杂志, 2013, 54(6): 451-455.
[28] 庄铭, 安佳丽, 钟梦媛, 等. 中医药临床疗效评价方法研究进展[J]. 中国中药杂志, 2023, 48(12): 3263-3268.
[29] 周雪忠, 王世华, 张迪, 等. 构建中医药特色真实世界临床研究新模式的实践与思考[J]. 科技导报, 2023, 41(14): 22-31.
[30] 崔杰, 谈力欣. 辨病、辨证配穴针刺治疗糖尿病周围神经 病变 临床 研究[J]. 河北 中医, 2023, 45(7): 1160- 1163.
